SEC Filings Spark Interest: Recent regulatory disclosures have drawn attention from market participants monitoring Gossamer Bio's pipeline developments. Traders highlight multiple 8-K filings as potential precursors to meaningful clinical progress. Discussions center on the implications for near-term volatility in the shares.
Phase Transition Buzz: Social media commentary frequently references signals pointing to an advancement from Phase 2 to Phase 3 studies. Observers note short holding periods tied to these catalysts, with price targets clustered around modest gains from current levels. The conversation remains focused on execution risks inherent in biotech timelines.
Market Sentiment Snapshot: Overall tone reflects speculative engagement rather than broad consensus, with repeated alerts on entry zones near recent trading ranges. Participants emphasize data-driven patterns over long-term forecasts. Volatility expectations appear elevated amid the ongoing chatter.
Note: This discussion summary was generated from an AI condensation of post data.
Gossamer Bio Hedge Fund Activity
We have seen 86 institutional investors add shares of Gossamer Bio stock to their portfolio, and 135 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 40,760,576 shares (+20512.7%) to their portfolio in Q2 2026, for an estimated $6,709,190
- DEEPCURRENTS INVESTMENT GROUP LLC added 37,665,073 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,199,671
- 683 CAPITAL MANAGEMENT, LLC added 34,198,868 shares (+684.0%) to their portfolio in Q2 2026, for an estimated $5,629,133
- CONTEXT CAPITAL MANAGEMENT, LLC added 28,946,459 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,764,587
- WORTH VENTURE PARTNERS, LLC added 25,017,881 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,117,943
- GSA CAPITAL PARTNERS LLP added 14,935,087 shares (+28798.9%) to their portfolio in Q2 2026, for an estimated $2,458,315
- WOLVERINE ASSET MANAGEMENT LLC added 12,894,746 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,122,475
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Gossamer Bio Price Targets
Multiple analysts have issued price targets for $GOSS recently. We have seen 2 analysts offer price targets for $GOSS in the last 6 months, with a median target of $1.14.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $2.0 on 06/25/2026
- Eliana Merle from Barclays set a target price of $0.28 on 05/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
